The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends of the investing world.
The bottom line is that over the long term, earnings growth goes hand in hand with the biggest winners. On that note, here are three market-beating stocks with room for further growth.
Marvell Technology (MRVL)
Five-Year Return: +329%
Moving away from a low margin storage device management chips in one of the biggest semiconductor business model pivots of the past decade, Marvell Technology (NASDAQ: MRVL) is a fabless designer of special purpose data processing and networking chips used by data centers, communications carriers, enterprises, and autos.
Why Does MRVL Stand Out?
- Annual revenue growth of 22.5% over the last five years was superb and indicates its market share increased during this cycle
- Operating margin expanded by 23.9 percentage points over the last five years as it scaled and became more efficient
- Incremental sales over the last five years have been more profitable as its earnings per share increased by 25.1% annually, topping its revenue gains
Marvell Technology’s stock price of $183.54 implies a valuation ratio of 46.9x forward P/E. Is now the time to initiate a position? Find out in our full research report, it’s free.
Gilead Sciences (GILD)
Five-Year Return: +91.4%
From its groundbreaking work in developing the first single-tablet regimens for HIV treatment, Gilead Sciences (NASDAQ: GILD) develops and markets innovative medicines for life-threatening diseases including HIV, viral hepatitis, COVID-19, and cancer.
Why Should GILD Be on Your Watchlist?
- $29.73 billion in revenue gives its scale, which leads to bargaining power with customers because there are few trusted alternatives
- Adjusted operating profits increased over the last two years as the company gained some leverage on its fixed costs and became more efficient
- GILD is a free cash flow machine with the flexibility to invest in growth initiatives or return capital to shareholders
Gilead Sciences is trading at $132.20 per share, or 29.5x forward EV-to-EBITDA. Is now a good time to buy? See for yourself in our comprehensive research report, it’s free.
Cencora (COR)
Five-Year Return: +121%
Formerly known as AmerisourceBergen until its 2023 rebranding, Cencora (NYSE: COR) is a global pharmaceutical distribution company that connects manufacturers with healthcare providers while offering logistics, data analytics, and consulting services.
Why Are We Backing COR?
- Unparalleled scale of $328.7 billion in revenue enables it to spread administrative costs across a larger membership base
- Share repurchases have amplified shareholder returns as its annual earnings per share growth of 14.6% exceeded its revenue gains over the last five years
- Stellar returns on capital showcase management’s ability to surface highly profitable business ventures
At $260.90 per share, Cencora trades at 13.7x forward P/E. Is now the right time to buy? Find out in our full research report, it’s free.
Stocks We Like Even More
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum - both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks - FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
